EICHORPublic-registry site landscape for NCT07751848, “A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus”, a Lupus Erythematosus, Systemic study sponsored by AstraZeneca. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07751848 (registry record) |
| Study title | A Study of Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Mod-severe Systemic Lupus Erythematosus |
| Official title | Multicentre, Open-Label, Single-Arm, 52-Week, Ph3b Study to Evaluate the Efficacy and Safety Outcomes in Chinese Patients Treated With Anifrolumab Who Have Active Moderate-Severe Systemic Lupus Erythematosus (SLE) |
| Sponsor | AstraZeneca |
| Condition(s) | Lupus Erythematosus, Systemic |
| Phase | PHASE3 |
| Listed sites | 44 |
| Intervention(s) | Anifrolumab |
| Site countries | China |
Patient-friendly overview of this study: eichor.com/study/NCT07751848.
Eichor generates a preliminary site-risk snapshot for NCT07751848 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
